Regen BioPharma Inc (RGBP)

[aheadofthecurve]

Regen BioPharma's Chairman and CEO, David Koos, stated, "In the beginning, Regen's business model was created with the goal of developing intellectual property to a point of attracting large pharmaceutical companies, to participate in maturing Company assets, either by sale, license or co-development. By forming CheckPoint Immunology, we are setting our game plan in place so that as we get further along in our development of small molecule therapies for treating cancer and autoimmune diseases, we can structure a transaction specific to NR2F6-related therapies. The Company has been approached by numerous parties interested in our NR2F6 based therapies. We expect, as we further optimize our small molecule compounds, there should be even greater interest. Hence the reason for creating CheckPoint Immunology is as a pure vehicle for any future NR2F6 transaction."